I agree that an "outlicensing" with $45mil to put in the bank has become low probability. I think that the progress on AdCella shows TO's confidence in the viability of the group. And to me that implies there will be a deal of sorts in say the next 3 months. Of course I hope it is sooner rather than later.
For a co-development, I just hope the partner has to commit a significant amount into the bank account of AdSolis/JV, and not just commit to taking on the costs. I think that the market may not revalue 1AD shares unless there is a transfer of $$$ rather than an equity investment by a Big Pharma. Compare the recent investment by Lantheus into RAD. That type of deal could unfortunately mean that shareholders have a much longer wait to see value.
1AD Price at posting:
1.8¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)